Moleculin Biotech
$2.5
83
+$0.01+0.4% Today
Statistics
Day High
2.55
Day Low
2.48
52W High
27
52W Low
1.96
Volume
68,732
Avg. Volume
-
Mkt Cap
127.28M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
7MayExpected
Expected EPS
-1.663333
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-43.53MNet Income
Analyst Ratings
22Average Price Target
The highest estimate is 22.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow MBRX. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap163.4B
AMGEN
AMGN
Mkt Cap178B
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Merck
MRK
Mkt Cap277.02B
Pfizer
PFE
Mkt Cap149.77B
Novartis
NVS
Mkt Cap279.67B
Abbvie
ABBV
Mkt Cap365.43B
Lilly(Eli) &
LLY
Mkt Cap862.01B
Astrazeneca
AZN
Mkt Cap286.4B
Regeneron Pharmaceuticals
REGN
Mkt Cap73.54B
About
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas.
Show more...
CEO
Mr. Walter V. Klemp
Employees
17
Country
United States
ISIN
US60855D4088
Listings
0 Comments
Share your thoughts
FAQ
What is Moleculin Biotech stock price today?▼
The current price of MBRX is $2.5 USD — it has increased by +0.4% in the past 24 hours. Watch Moleculin Biotech stock price performance more closely on the chart.
What is Moleculin Biotech stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Moleculin Biotech stocks are traded under the ticker MBRX.
Is Moleculin Biotech stock price growing?▼
MBRX stock has risen by +1.2% compared to the previous week, the month change is a +9.48% rise, over the last year Moleculin Biotech has showed a -90.04% decrease.
What is Moleculin Biotech market cap?▼
Today Moleculin Biotech has the market capitalization of 127.28M
When is the next Moleculin Biotech earnings date?▼
Moleculin Biotech is going to release the next earnings report on May 07, 2026.
What were Moleculin Biotech earnings last quarter?▼
MBRX earnings for the last quarter are 2.61 USD per share, whereas the estimation was -6.11 USD resulting in a +142.69% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Moleculin Biotech revenue for the last year?▼
Moleculin Biotech revenue for the last year amounts to 0 USD.
What is Moleculin Biotech net income for the last year?▼
MBRX net income for the last year is -43.53M USD.
How many employees does Moleculin Biotech have?▼
As of May 06, 2026, the company has 17 employees.
In which sector is Moleculin Biotech located?▼
Moleculin Biotech operates in the Health & Wellness sector.
When did Moleculin Biotech complete a stock split?▼
The last stock split for Moleculin Biotech was on December 01, 2025 with a ratio of 1:25.
Where is Moleculin Biotech headquartered?▼
Moleculin Biotech is headquartered in Houston, United States.